News | October 30, 2023
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
The companies plan to start a pivotal Phase 3 trial in the coming months
The companies plan to start a pivotal Phase 3 trial in the coming months
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The company is confident of addressing all the observations within the stipulated time
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
